ReCode Therapeutics
ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver.
Series B+ ·
Amount not disclosed in a source on record.
Funding history ↓Signals
Website registeredDec 6, 2015 (10 years old)
About ReCode Therapeutics
Our pipeline of rare disease therapeutics uses optimized mRNA and gene correction with redosing capability.
Funding rounds
- Series B+ · amount undisclosedSource: fundraisingfox.com
- Website created
Companies like ReCode Therapeutics
AAddition Therapeutics$100M Series A · Dec 2025
SSplice Bio$140M Series B+ · Jun 2025
CCity TherapeuticsSeries B+ · Aug 2026
AAlia Therapeutics$5M Seed · Apr 2023HHotSpot Therapeutics$100M Series B+ · Nov 2021
MMatchpoint Therapeutics$150M Series B+ · Oct 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/recode-therapeutics (get a free API key).